Canine clinical trials may be an appealing first step in testing MCL1 inhibition in osteosarcoma because AZD5991 and other MCL1 targeting drugs bind to canine MCL1 and human MCL1 with similar affinity, likely due to the fact that MCL1 is nearly identical in these species [39–41]. This evidence concerns the gene MCL1 and osteosarcoma.